Heart Failure Pipeline Analysis Demonstrates Novel 75+ Therapies at the Horizon Expected to Transform the Treatment Paradigm | DelveInsight
DelveInsight’s, “Heart Failure Pipeline Insight, 2023,” report provides comprehensive insights about 75+ companies and 90+ pipeline drugs in the Heart Failure pipeline landscape. It covers the Heart Failure pipeline drug profiles, including Heart Failure clinical trials and nonclinical stage products. It also covers the Heart Failure pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive Heart Failure pipeline products in this space.
In the Heart Failure Pipeline Report, detailed description of the drug is given which includes mechanism of action of the drug, Heart Failure clinical trials studies, Heart Failure NDA approvals (if any), and product development activities comprising the technology, Heart Failure collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Key takeaways from the Heart Failure Pipeline Report
- DelveInsight’s Heart Failure Pipeline report depicts a robust space with 75+ active players working to develop 90+ pipeline therapies for Heart Failure treatment.
- The leading Heart Failure Companies includes Zensun (Shanghai) Sci & Tech, Windtree Therapeutics, TreeFrog Therapeutics, Torrent Pharmaceuticals, Tenaya Therapeutics, Tasly Pharmaceuticals, Sulfagenix, Stealth BioTherapeutics, SQ Innovation, Shanghai Hongyitang Biopharmaceutical Technology, scPharmaceuticals, Sardocor, Sana Biotechnology, Salubris Biotherapeutics, Roche, Rivus Pharmaceuticals, Ribomic, Renova Therapeutics, Relaxera, Regeneron Pharmaceuticals, Recardio, and others.
- Promising Heart Failure Pipeline Therapies includes CXL-1020, Strata 1 CXL-1020, Ularitide, Allogeneic Mesenchymal Bone Marrow Cells (aMBMC), Lactated Ringer’s Solution, Bisoprolol, Empagliflozin, Lixivaptan, and others.
- The Heart Failure Companies and academics are working to assess challenges and seek opportunities that could influence Heart Failure R&D. The Heart Failure pipeline therapies under development are focused on novel approaches to treat/improve Heart Failure.
To explore more information on the latest breakthroughs in the Heart Failure Pipeline treatment landscape of the report, click here @ Heart Failure Pipeline Outlook
Heart Failure Overview
Heart failure (HF) is a syndrome caused by structural and functional defects in myocardium resulting in impairment of ventricular filling or the ejection of blood. The most common cause for HF is reduced left ventricular myocardial function. Major pathogenic mechanisms leading to HF are increased hemodynamic overload, ischemia-related dysfunction, ventricular remodeling, excessive neuro-humoral stimulation, abnormal myocyte calcium cycling, excessive or inadequate proliferation of the extracellular matrix, accelerated apoptosis and genetic mutations. Heart failure is a pathological condition in which the heart is unable to pump enough blood to the rest of the body, because it is either unable to fill with a sufficient volume of blood or unable to generate sufficient force to pump out enough blood. Dysfunction of the pericardium, myocardium, endocardium, heart valves or great vessels alone or in combination is also associated with HF.
Latest Developmental Activities in the Heart Failure Treatment Landscape
- In May 2020, Amgen and Cytokinetics, Incorporated announced that the U.S. Food and Drug Administration (FDA) had granted Fast Track designation for omecamtiv mecarbil, a novel selective cardiac myosin activator, also known as a cardiac myotrope, being developed for the potential treatment of chronic heart failure with reduced ejection fraction (HFrEF).
- In January 2020, Arena Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation for APD418, a β3-adrenergic receptor (AdrR) antagonist and cardiac myotrope, in development for the treatment of decompensated heart failure (DHF).
For further information, refer to the detailed Heart Failure Unmet Needs, Heart Failure Market Drivers, and Heart Failure Market Barriers, click here for Heart Failure Ongoing Clinical Trial Analysis
Heart Failure Emerging Drugs Profile
Tirzepatide: Eli Lilly and Company
Tirzepatide is a once-weekly dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist that integrates the actions of both incretins into a single novel molecule. GIP is a hormone that may complement the effects of GLP-1. In preclinical models, GIP has been shown to decrease food intake and increase energy expenditure therefore resulting in weight reductions, and when combined with a GLP-1 receptor agonist, may result in greater effects on glucose and body weight. Tirzepatide is in phase 3 development for chronic weight management and heart failure with preserved ejection fraction (HFpEF).
Finerenone (BAY94-8862): Bayer
Finerenone (BAY 94-8862) is an investigational novel, non-steroidal, selective mineralocorticoid receptor antagonist (MRA) that has been shown to block the harmful effects of the overactivated mineralocorticoid receptor (MR) system. MR overactivation is a major driver of heart and kidney damage. Current steroidal MRAs on the market have proven to be effective in reducing cardiovascular mortality in patients suffering from heart failure with reduced ejection fraction (HFrEF). However, they are often underutilized due to the incidence of hyperkalemia, renal dysfunction, and anti-androgenic / progestogenic side effects.
The initiation of the Phase III FINEARTS-HF study (FINerenone trial to investigate Efficacy and sAfety superioR to placebo in paTientS with Heart Failure) builds upon the robust Phase II studies ARTS-HF and ARTS-DN which investigated the efficacy and safety of finerenone in patients with heart failure and chronic kidney disease, respectively. Data from the Phase II study program ARTS were presented at ESC Congress 2015 in London.
CardiAMP Cell Therapy: BioCardia
CardiAMP Cell Therapy uses a patient’s own (autologous) bone marrow cells delivered to the heart in a minimally invasive, catheter-based procedure to potentially stimulate the body’s natural healing response. The CardiAMP Cell Therapy Heart Failure Trial is the first multicenter clinical trial of an autologous cell therapy to prospectively screen for cell therapeutic potency in order to improve patient outcomes. CardiAMP Cell Therapy incorporates three proprietary elements not previously utilized in investigational cardiac cell therapy, which the company believes improves the probability of success of the treatment: a pre-procedural diagnostic for patient selection, a high target dosage of cells, and a proprietary delivery system that has been shown to be safer than other intramyocardial delivery systems and more successful for enhancing cell retention.
Firibastat: Quantum Genomics
Firibastat is the first drug candidate in a new class of therapeutic agents called BAPAIs (Brain Aminopeptidase an Inhibitors). Firibastat is a prodrug that releases EC33, a specific and selective inhibitor of Aminopeptidase A in the brain, thereby preventing the production of angiotensin III in the brain. After collecting excellent data on animal efficacy and human safety in the Phase IIa study, Quantum Genomics announced the design of its Phase IIb study in heart failure last June 2018 with Firibastat. Firibastat currently is in Phase II for the Heart Failure.
HU 6: Rivus Pharmaceuticals
HU6 is a controlled metabolic accelerator (CMA) that provides a novel, measured approach to activating proton leak and mitochondrial uncoupling, a natural process in the body that regulates and dissipates energy. By ferrying protons out of the mitochondrial intermembrane space, CMAs cue the increased oxidation of sugars and fats, while maintaining the same baseline production of adenosine triphosphate (ATP). Activating this process results in the reduction of accumulated fat throughout the body.
Heart Failure Pipeline Therapeutics Assessment
There are approx. 75+ key companies which are developing the therapies for Heart Failure. The companies which have their Heart Failure drug candidates in the most advanced stage, i.e. Phase III include, Eli Lilly and Company
Request a sample and discover the recent advances in Heart Failure Ongoing Clinical Trial Analysis and Medications, click here @ Heart Failure Treatment Landscape
Scope of the Heart Failure Pipeline Insight Report
- Coverage- Global
- Heart Failure Companies- Zensun (Shanghai) Sci & Tech, Windtree Therapeutics, TreeFrog Therapeutics, Torrent Pharmaceuticals, Tenaya Therapeutics, Tasly Pharmaceuticals, Sulfagenix, Stealth BioTherapeutics, SQ Innovation, Shanghai Hongyitang Biopharmaceutical Technology, scPharmaceuticals, Sardocor, Sana Biotechnology, Salubris Biotherapeutics, Roche, Rivus Pharmaceuticals, Ribomic, Renova Therapeutics, Relaxera, Regeneron Pharmaceuticals, Recardio, and others.
- Heart Failure Pipeline Therapies- CXL-1020, Strata 1 CXL-1020, Ularitide, Allogeneic Mesenchymal Bone Marrow Cells (aMBMC), Lactated Ringer’s Solution, Bisoprolol, Empagliflozin, Lixivaptan, and others.
- Heart Failure Pipeline Segmentation: Product Type, Molecule Type, Mechanism of Action, Route of Administration
Dive deep into rich insights for drugs for Heart Failure Market Drivers and Heart Failure Market Barriers, click here @ Heart Failure Unmet Needs and Analyst Views
Table of Content
- Introduction
- Executive Summary
- Heart Failure : Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Heart Failure – DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Tirzepatide: Eli Lilly and Company
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- HU 6: Rivus Pharmaceuticals
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- HiCM 188: Help Therapeutics
- Drug profiles in the detailed report…..
- Inactive Products
- Heart Failure – Collaborations Assessment- Licensing / Partnering / Funding
- Heart Failure – Unmet Needs
- Heart Failure – Market Drivers and Barriers
- Appendix
Got Queries? Find out the related information on Heart Failure Mergers and acquisitions, Heart Failure Licensing Activities @ Heart Failure Emerging Drugs, and Recent Trends
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media Contact
Company Name: DelveInsight
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV 89107
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services
